Option chain shows key data for Oncolytics Biotech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Oncolytics Biotech.

Oncolytics Biotech (NASDAQ:ONCY) Stock, Option Chain

Oncolytics Biotech

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.

Screenshot 2024-08-13 at 5.40.41 PM

Biotech

General

ONCY

Extending Survival: Oncolytics Biotech&#39;s Pelareorep Shows Promise In Fighting Metastatic Breast Cancer

Screenshot 2024-07-29 at 6.05.52 PM

Pancreatic Cancer Could Overtake Colorectal Cancer To Become Second Leading Cause Of Cancer Death – Oncolytics Is Working On A Promising Treatment

Screenshot 2024-03-06 at 6.25.21 PM

Oncolytics Biotech (NASDAQ: ONCY) (TSX: ONC) Fights Cancer With Pelareorep, Which Has Received FDA Fast Track Designation For Breast And Pancreatic Cancer

Oncolytics Biotech Inc

News

Events

Oncolytics Biotech To Present At 2025 ASCO GI Symposium Jan. 23-25

This cohort is evaluating pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq&#xAE;) in newly diagnosed pancreatic ductal adenocarcinoma (PDAC) patients.

Oncolytics Biotech Says Germany's Medical Regulatory Body, The Paul-Ehrlich-Institute (PEI), Has Approved The Continuation Of Patient Enrollment Into Cohort 5 Of The GOBLET Study

Oncolytics Biotech Reveals Presentation Of Two Data Sets Through Two Abstracts Showcasing Pelareorep's Potential In Difficult-to-treat Gastrointestinal Cancers At ASCO

Oncolytics Biotech Completes Initial Safety Phase Enrollment For GOBLET Trial's Pancreatic Cancer Cohort

RBC Capital analyst Douglas Miehm reiterates Oncolytics Biotech (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ONC#TSX">ONC</a>) with a Outperform and maintains C$6 price target.

Price Target

Reiteration

Analyst Ratings

TSX:ONC

RBC Capital Reiterates Outperform on Oncolytics Biotech, Maintains C$6 Price Target

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Oncolytics Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) with a Buy and maintains $5 price target.

HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target

Earnings

Guidance

Health Care

Oncolytics Biotech Reported Q3 $19.6M In Cash And Cash Equivalents, Projected To Provide Cash Runway Through Key Milestones And Into 2025

Oncolytics Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 20 percent.

Oncolytics Biotech Q3 2024 GAAP EPS C$(0.12) Misses C$(0.10) Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Oncolytics Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) is gearing up to announce its quarterly earnings on Tuesday, 2024-11-12. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Oncolytics Biotech will report an earnings per share (EPS) of $-0.07.
Anticipation surrounds Oncolytics Biotech's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Performance in Previous Earnings</h3>
The company's EPS missed by $0.00 in the last quarter, leading to a 0.97% drop in the share price on the following day.
Here's a look at Oncolytics Biotech's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.07</td>
<td>-0.08</td>
<td>-0.11</td>
<td>-0.100</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.07</td>
<td>-0.07</td>
<td>-0.04</td>
<td>-0.104</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-6.0%</td>
<td>1.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731351758_0.png" alt="eps graph" />
<h3>Market Performance of Oncolytics Biotech's Stock</h3>
Shares of Oncolytics Biotech were trading at $1.07 as of November 08. Over the last 52-week period, shares are down 26.03%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/ONCY/earnings">To track all earnings releases for Oncolytics Biotech visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Oncolytics Biotech

WIIM

Oncolytics Biotech shares are trading higher after the company announced key progress and upcoming studies for breast and pancreatic cancer treatments while also preparing for an accelerated FDA approval path.

Oncolytics Biotech Announces Key Progress And Upcoming Studies For Breast And Pancreatic Cancer Treatments, Prepares For FDA Accelerated Approval Path

Confirmed overall response rate (ORR) was&nbsp;37.5%&nbsp;for pelareorep + paclitaxel and&nbsp;13.3%&nbsp;for paclitaxel.&nbsp;As previously reported, ORRs at week 16 (the trial&#39;s primary endpoint) in the pelareorep + paclitaxel and paclitaxel monotherapy cohorts were&nbsp;31%&nbsp;and&nbsp;20%, respectively.
&quot;The fact that the median overall survival was not reached because more than half the patients were still alive at the end of the study is a remarkable achievement for us,&quot; said&nbsp;Wayne Pisano, Interim CEO and Chair of Oncolytics&#39; Board of Directors.
&nbsp;

Oncolytics Reports Clinical Results From BRACELET-1 Study; Says Overall Survival Results Corroborate Results Of Previous Randomized IND-213 Breast Cancer Study

Oncolytics Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 22.22 percent increase over losses of $(0.09) per share from the same period last year.

Oncolytics Biotech Q2 GAAP EPS $(0.07), Inline

&nbsp;
Oncolytics Biotech&reg;&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ONC#TSX">ONC</a>), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced that the Company received productive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC). The FDA supports progression-free survival as the primary endpoint of the study, with overall survival as a key secondary endpoint. The Company&#39;s proposed study will enroll patients who have failed hormonal therapy and have received no more than one line of antibody-drug conjugate (ADC) therapy.

Government

Regulations

Oncolytics Biotech Advances Breast Cancer Trial with FDA Support

&nbsp;Oncolytics Biotech&reg;&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ONC#TSX">ONC</a>), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced that&nbsp;Matt Coffey, PhD, President and Chief Executive Officer of Oncolytics will take a medical leave of absence, effective immediately.&nbsp;Wayne Pisano, Chair of Oncolytics&#39; Board of Directors, will serve as the interim CEO during Dr. Coffey&#39;s absence.
<img alt="Oncolytics_Biotech_New_Logo" src="https://mma.prnewswire.com/media/1762876/Oncolytics_Biotech_New_Logo.jpg" />
&quot;On behalf of the Board, I would like to wish Matt a swift recovery. In the interim, the Board and I are highly confident in our tenured executive team&#39;s ability to continue executing our mission, achieve our strategic priorities, and drive forward our registration-enabling clinical plans for pelareorep, a differentiated and potentially leading immunotherapeutic agent in breast and pancreatic cancers,&quot; said&nbsp;Wayne Pisano, Chair of Oncolytics&#39; Board of Directors. &quot;Together, we will continue to deliver on our long-term goals to ultimately bring pelareorep to patients with cancer.&quot;
Wayne Pisano, Chair of the Board since 2013, has more than 30 years of experience as a pharmaceutical industry executive and over 12 years of experience in the biotech industry. Mr. Pisano served as the president of VaxInnate, a privately held biotech company, and has served as a Board Director of several biotech companies, including Provention Bio and Altimmune Inc. He served as Chairman of&nbsp;Provention Bio for four years, overseeing the company&#39;s acquisition by Sanofi in&nbsp;April 2023.
Mr. Pisano is the former President and CEO of Sanofi Pasteur, one of the largest vaccine companies in the world. He is credited with driving Sanofi Pasteur&#39;s leadership within the worldwide influenza market, capturing&nbsp;50%&nbsp;of global sales. He also laid the foundation for the company&#39;s global pediatric vaccines strategy and bolstered the Sanofi Pasteur pipeline with the acquisition of Acambis PLC, a biotech based in&nbsp;Boston, in 2008 and Shantha Biotechnics, a highly regarded Indian vaccine company in 2010. Prior to joining Sanofi Pasteur, he spent 11 years with Novartis (formerly Sandoz). He has a bachelor&#39;s degree in biology from St. John Fisher University in&nbsp;New York&nbsp;and an MBA from the&nbsp;University of Dayton&nbsp;in&nbsp;Ohio.

Management

Oncolytics Biotech Chair Wayne Pisano To Serve As Interim CEO As Dr. Matt Coffey Looks To Take Medical Leave Of Absence

SAN DIEGO, and&nbsp;CALGARY, AB,&nbsp;June 20, 2024&nbsp;/PRNewswire/ -- Oncolytics Biotech&reg;&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ONC#TSX">ONC</a>), a leading clinical-stage company specializing in immunotherapeutics for oncology, announced the dosing of the first patient in the new GOBLET study cohort evaluating pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq&reg;) in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The co-primary endpoints of the cohort are objective response rate (ORR) and safety. It is supported by the&nbsp;US$5M&nbsp;Pancreatic Cancer Action Network (PanCAN) Therapeutic Accelerator Award, an innovative program established to accelerate the development of new treatments for pancreatic cancer patients. It will be conducted in collaboration with AIO-Studien-gGmbH (AIO), a clinical trial group within the German Cancer Society, as part of GOBLET, a Phase 1/2 multiple indication study evaluating pelareorep-based combinations in gastrointestinal cancers.

Oncolytics Biotech Begins New Study for Advanced Pancreatic Cancer Treatment

Opinion

Press Releases

Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

Small Cap

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus

Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium

Comments

Oncolytics Biotech

Oncolytics Biotech (ONCY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga